# Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Clinical trial · BioNTech SE

- Archive id: nct:NCT06712316
- Published: 2024-12-02
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06712316
- Source URL: https://clinicaltrials.gov/study/NCT06712316
- Provenance: clinicaltrials

## Abstract

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: RECRUITING
- phase: PHASE2, PHASE3
- study type: INTERVENTIONAL
- enrollment: 1580
- sponsor: BioNTech SE
- conditions: Non-small Cell Lung Cancer
- interventions: DRUG: Pumitamig; DRUG: Pembrolizumab; DRUG: Carboplatin; DRUG: Pemetrexed; DRUG: Paclitaxel
- start date: 2025-01-07
- start date type: ACTUAL
- primary completion date: 2029-01-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.